CCEL - CRYO-CELL International, Inc. Stock Price, Fair Value and News

9.02USD+0.45 (+5.25%)Market Closed

Market Summary

USD9.02+0.45

Market Closed

5.25%

CCEL Stock Price

View Fullscreen

CCEL RSI Chart

CCEL Valuation

Market Cap

73.1M

Price/Earnings (Trailing)

-7.51

Price/Sales (Trailing)

2.33

EV/EBITDA

-6.13

Price/Free Cashflow

-34.4K

CCEL Price/Sales (Trailing)

CCEL Profitability

EBT Margin

-43.94%

Return on Equity

94.14%

Return on Assets

-15.77%

Free Cashflow Yield

CCEL Fundamentals

CCEL Revenue

Revenue (TTM)

31.4M

Rev. Growth (Yr)

0.36%

Rev. Growth (Qtr)

-0.31%

CCEL Earnings

Earnings (TTM)

-9.7M

Earnings Growth (Yr)

-27.46%

Earnings Growth (Qtr)

104.97%

Breaking Down CCEL Revenue

Last 7 days

6.8%

Last 30 days

19.3%

Last 90 days

64.3%

Trailing 12 Months

80.4%

How does CCEL drawdown profile look like?

CCEL Financial Health

Current Ratio

0.49

Debt/Equity

-0.14

Debt/Cashflow

4.86

CCEL Investor Care

Dividend Yield

12.48%

Dividend/Share (TTM)

0.9

Buy Backs (1Y)

2.40%

Diluted EPS (TTM)

-1.16

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	31.4M	0	0	0
2023	30.9M	31.0M	31.2M	31.3M
2022	29.3M	29.7M	29.9M	30.3M
2021	30.4M	29.7M	29.1M	28.9M
2020	31.9M	31.7M	31.6M	31.1M
2019	30.5M	32.1M	32.4M	31.8M
2018	25.8M	26.1M	27.1M	29.2M
2017	23.8M	24.2M	24.8M	25.4M
2016	21.4M	22.2M	23.1M	23.1M
2015	19.6M	19.8M	20.3M	21.1M
2014	19.7M	19.7M	19.9M	20.1M
2013	18.4M	18.8M	19.1M	19.0M
2012	17.6M	17.4M	17.6M	18.0M
2011	17.8M	17.8M	17.9M	17.9M
2010	0	0	0	17.8M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of CRYO-CELL International, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Nov 18, 2022	portnoy david	bought	2,616	4.89985	534	chairman, co-ceo
Nov 17, 2022	portnoy david	bought	2,528	4.9	516	chairman, co-ceo
Nov 15, 2022	portnoy david	sold	-76,860	4.80375	-16,000	chairman, co-ceo
Nov 15, 2022	portnoy david	bought	45,556	4.8	9,491	chairman, co-ceo
Nov 14, 2022	portnoy david	bought	48,000	4.8	10,000	chairman, co-ceo
Nov 14, 2022	portnoy david	sold	-48,000	4.8	-10,000	chairman, co-ceo
Nov 11, 2022	portnoy david	sold	-45,471	4.78896	-9,495	chairman, co-ceo
Nov 11, 2022	portnoy david	bought	28,710	4.785	6,000	chairman, co-ceo
Nov 10, 2022	portnoy david	sold	-	-	-9,122	chairman, co-ceo
Nov 10, 2022	portnoy david	sold	-	-	-9,974	chairman, co-ceo

Which funds bought or sold CCEL recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
May 01, 2024	HAMILTON LANE ADVISORS LLC	unchanged	-	700,646	3,056,620	2.16%
Apr 09, 2024	MASSMUTUAL TRUST CO FSB/ADV	reduced	-2.78	171,596	828,321	0.03%
Apr 08, 2024	ROWLANDMILLER & PARTNERS.ADV	new	-	107,670	107,670	0.02%
Mar 11, 2024	VANGUARD GROUP INC	added	8.65	82,824	524,049	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	new	-	12.00	12.00	-%
Feb 14, 2024	Royal Bank of Canada	added	10,200	1,000	1,000	-%
Feb 13, 2024	NORTHERN TRUST CORP	new	-	151,226	151,226	-%
Feb 13, 2024	MORGAN STANLEY	added	50.00	1,346	3,450	-%
Feb 13, 2024	BlackRock Inc.	reduced	-1.18	5,661	76,187	-%

Are Funds Buying or Selling CCEL?

Are funds buying CCEL calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CCEL

No. of Funds

Unveiling CRYO-CELL International, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2023	iszo capital lp	2.3%	195,031	SC 13G/A
Feb 14, 2022	iszo capital lp	5.7%	482,931	SC 13G/A

Recent SEC filings of CRYO-CELL International, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 15, 2024	10-Q	Quarterly Report
Mar 26, 2024	8-K	Current Report
Feb 28, 2024	10-K	Annual Report

Peers (Alternatives to CRYO-CELL International, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
UNH	454.0B	371.6B	7.11%	1.06%	20.29	1.22	14.64%	11.24%
CI	97.0B	206.0B	-5.44%	40.10%	25.17	0.47	12.55%	-43.95%
HCA	80.6B	66.7B	-7.36%	10.85%	14.74	1.21	9.59%	-4.59%
CVS	70.2B	360.9B	-25.07%	-18.74%	9.58	0.19	9.07%	78.49%
CNC	39.9B	155.5B	2.42%	11.29%	14.6	0.26	6.34%	84.42%
DVA	11.8B	12.3B	-0.62%	54.17%	14.46	0.96	5.77%	58.74%
UHS	11.6B	14.3B	-3.48%	18.85%	16.19	0.81	6.59%	6.24%
MID-CAP
CHE	8.5B	2.3B	-11.39%	3.11%	30	3.71	5.96%	18.29%
ACHC	6.1B	3.0B	-12.79%	-3.18%	-542.9	2.05	10.92%	-104.06%
AMN	2.3B	3.8B	2.01%	-30.11%	10.69	0.59	-27.73%	-52.50%
AMEH	2.1B	1.4B	-11.02%	9.69%	34.19	1.5	21.19%	34.42%
SMALL-CAP
ADUS	1.6B	1.1B	-4.40%	21.46%	25.46	1.5	11.31%	35.83%
BKD	1.4B	3.0B	10.96%	93.54%	-7.5	0.47	6.74%	20.73%
BEAT	58.7M	-	6.70%	1.83%	-4.01	-	-	-12.94%
AMS	18.5M	21.3M	3.05%	8.96%	34.8	0.87	8.00%	-62.25%

CRYO-CELL International, Inc. News

Latest updates

CRYO-CELL International, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-0.3%	7,852	7,877	7,870	7,773	7,824	7,764	7,681	7,633	7,259	7,315	7,504	7,205	6,861	7,541	8,114	7,872	7,621	7,970	8,223	8,128	7,495
Costs and Expenses	-70.8%	7,031	24,053	6,709	6,745	6,141	7,359	6,727	6,439	5,788	8,124	5,907	5,210	5,625	5,360	5,634	6,120	6,372	6,251	6,230	7,631	6,641
S&GA Expenses	-19.5%	4,340	5,393	3,805	4,039	3,879	4,688	3,603	3,913	3,376	4,535	3,494	3,148	3,433	3,490	3,376	3,559	3,870	3,942	3,557	3,648	3,745
R&D Expenses	13.3%	503	444	344	305	79.00	76.00	80.00	81.00	147	30.00	10.00	3.00	6.00	7.00	1.00	10.00	6.00	17.00	2.00	5.00	6.00
EBITDA Margin	-7.9%	-0.38*	-0.35*	0.20*	0.19*	0.20*	0.20*	0.13*	0.15*	0.18*	0.17*	0.26*	0.24*	0.22*	-	-	-	-	-	-	-	-
Interest Expenses	251.7%	256	-169	470	470	466	574	365	277	306	421	336	341	280	475	339	365	365	458	414	424	407
Income Taxes	105.0%	238	-4,803	387	125	448	-215	174	265	324	-606	405	471	259	631	152	380	252	446	499	51.00	105
Earnings Before Taxes	105.0%	795	-15,993	1,068	346	1,215	623	641	900	1,156	-1,243	1,261	1,641	952	1,831	936	1,333	939	1,291	1,615	105	381
EBT Margin	-3.1%	-0.44*	-0.43*	0.10*	0.09*	0.11*	0.11*	0.05*	0.07*	0.10*	0.09*	0.20*	0.18*	0.17*	-	-	-	-	-	-	-	-
Net Income	105.0%	556	-11,190	681	221	767	838	467	635	832	-637	856	1,171	694	1,200	784	953	687	845	1,116	54.00	276
Net Income Margin	-2.1%	-0.31*	-0.30*	0.08*	0.07*	0.09*	0.09*	0.04*	0.06*	0.08*	0.07*	0.13*	0.13*	0.12*	-	-	-	-	-	-	-	-
Free Cashflow	-150.0%	-814	1,629	-1,348	532	1,268	2,455	-8,549	1,640	859	1,387	528	1,527	2,650	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	0.8%	61,711	61,221	69,796	68,758	66,134	64,888	66,765	55,395	54,808	60,662	59,424	58,318	105,264	46,200	44,440	44,841	44,730	42,886	41,828	40,889	43,342
Current Assets	0.0%	9,452	9,453	9,936	10,313	10,637	9,610	11,141	10,305	9,717	15,783	14,921	14,783	18,696	18,556	16,764	17,280	16,895	15,388	15,920	15,002	30,376
Cash Equivalents	-39.1%	247	406	584	1,124	1,373	1,704	2,925	2,804	2,145	8,263	7,701	7,948	11,278	10,361	8,108	8,420	8,416	6,541	7,339	6,469	7,076
Inventory	-1.8%	755	769	1,063	879	900	851	919	873	928	921	834	890	868	927	1,203	1,054	1,103	1,085	1,032	1,046	16,133
Net PPE	2.9%	21,605	20,997	18,836	17,098	14,427	13,603	15,179	4,028	3,805	3,230	3,028	1,553	1,597	1,641	1,664	1,739	1,775	1,846	1,769	1,748	1,465
Goodwill	0%	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,941	1,941
Liabilities	-0.3%	72,049	72,252	69,813	69,616	66,822	66,412	69,151	50,988	50,557	56,478	54,625	54,315	106,960	48,865	48,476	49,823	50,731	49,839	48,791	48,983	51,577
Current Liabilities	-7.2%	19,370	20,864	18,563	19,708	18,912	19,481	23,624	15,711	16,387	21,074	19,858	20,120	29,845	16,415	14,428	15,099	16,070	15,429	14,267	13,611	15,279
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,425	1,425
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,425	1,425
Shareholder's Equity	6.3%	-10,338	-11,031	-	-	-687	-1,524	-	4,407	4,251	4,184	4,799	4,003	-	-	-	-	-	-	-	-	-
Retained Earnings	1.8%	-30,602	-31,159	-19,969	-20,649	-20,870	-21,637	-22,475	-15,269	-15,904	-16,736	-16,099	-16,955	-18,126	-18,819	-20,019	-20,804	-21,757	-22,444	-23,289	-24,405	-24,459
Additional Paid-In Capital	0.7%	43,718	43,411	43,236	43,067	42,911	42,597	42,446	41,768	41,650	41,587	41,315	41,377	36,858	36,582	36,410	36,248	36,184	35,919	35,761	35,747	35,660
Shares Outstanding	0%	8,287	8,287	8,287	8,287	8,443	8,501	8,390	8,479	8,527	8,552	7,996	7,760	7,571	-	-	-	-	-	-	-	-
Float	-	-	-	-	27,010	-	-	-	35,449	-	-	-	47,607	-	-	-	29,618	-	-	-	30,375	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-110.7%	-356	3,344	1,942	1,989	1,644	2,430	2,689	1,947	1,507	1,667	2,059	1,537	2,662	2,977	2,052	822	2,616	1,124	2,789	528	1,854
Share Based Compensation	75.7%	307	175	172	156	313	151	161	117	32.00	68.00	81.00	68.00	85.00	171	162	64.00	224	158	14.00	87.00	139
Cashflow From Investing	82.8%	-341	-1,981	-3,386	-1,574	-1,201	1,916	-11,226	84.00	-6,053	-290	-1,531	-4,966	-161	52.00	356	-43.27	-6.96	-154	-98.47	-359	-49.08
Cashflow From Financing	135.0%	539	-1,540	904	-663	-772	-5,566	8,657	-1,371	-1,571	-814	-775	100	-1,583	-775	-2,720	-775	-734	-1,767	-1,820	-775	-769
Buy Backs	-	170	-	8.00	548	243	127	267	596	829	249	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CCEL Income Statement

2024-02-29

Consolidated Statements of Income - USD ($)	3 Months Ended
Consolidated Statements of Income - USD ($)	Feb. 29, 2024	Feb. 28, 2023
Revenue	$ 7,852,235	$ 7,824,415
Costs and Expenses:
Cost of sales	2,160,468	2,067,364
Selling, general and administrative expenses	4,339,645	3,878,903
Change in fair value of contingent consideration	(5,176)	(164,701)
Research, development and related engineering	502,889	78,834
Depreciation and amortization	33,186	280,844
Total costs and expenses	7,031,012	6,141,244
Operating Income	821,223	1,683,171
Other Income (Expense):
Gains (losses) on marketable securities	274,971	(3,681)
Loss on interest rate swap	(45,288)	0
Other income	63	1,268
Interest expense	(256,459)	(466,231)
Total other income (expense)	(26,713)	(468,644)
Income before income tax expense	794,510	1,214,527
Income tax expense	(238,269)	(447,715)
Net income	$ 556,241	$ 766,812
Net income per common share - basic	$ 0.07	$ 0.09
Weighted average common shares outstanding - basic	8,277,844	8,467,074
Net income per common share - diluted	$ 0.07	$ 0.09
Weighted average common shares outstanding - diluted	8,325,027	8,474,737
Processing and Storage Fees [Member]
Revenue	$ 7,805,522	$ 7,561,518
Public Banking Revenue [Member]
Revenue	43,713	230,697
Product Revenue [Member]
Revenue	$ 3,000	$ 32,200

CCEL Balance Sheet

2024-02-29

Consolidated Balance Sheets - USD ($)	Feb. 29, 2024	Nov. 30, 2023
Current Assets
Cash and cash equivalents	$ 247,112	$ 406,067
Marketable securities	732,481	574,183
Accounts receivable (net of allowance for doubtful accounts of $3,939,638 and $3,822,300, respectively)	6,726,893	6,576,240
Prepaid expenses	535,295	615,407
Inventory, current portion	755,160	768,877
Swap contract	76,825	122,113
Other current assets	378,310	389,950
Total current assets	9,452,076	9,452,837
Property and Equipment-net	21,605,273	20,996,883
Other Assets
Intangible assets, net	972,154	989,121
Inventory, net of current portion	5,223,980	5,260,119
Goodwill	1,941,411	1,941,411
Deferred tax assets	20,492,749	20,492,749
Operating lease right-of-use asset	958,022	1,033,157
Deposits and other assets, net	757,109	746,493
Total other assets	30,653,425	30,771,050
Total assets	61,710,774	61,220,770
Current Liabilities
Accounts payable	2,996,658	3,174,584
Accrued expenses	3,916,898	5,170,809
Note payable	168,623	165,641
Line of credit	1,972,728	1,222,728
Current portion of operating lease liability	253,981	225,686
Duke license agreement liability	666,667	1,200,000
Deferred revenue	9,394,821	9,704,553
Total current liabilities	19,370,376	20,864,001
Other Liabilities
Deferred revenue, net of current portion	42,603,661	41,186,800
Contingent consideration	39,050	44,226
Note payable, net of current portion and debt issuance costs	8,391,738	8,430,037
Operating lease long-term liability	768,961	851,938
Long-term liability - revenue sharing agreements	875,000	875,000
Total other liabilities	52,678,410	51,388,001
Total liabilities	72,048,786	72,252,002
Commitments and contingencies (Note 9)	0	0
Stockholders' Deficit
Preferred stock	0	0
Common stock ($.01 par value, 20,000,000 authorized; 14,849,246 issued and 8,254,977 outstanding as of February 29, 2024 and 14,849,246 issued and 8,286,785 outstanding as of November 30, 2023)	148,492	148,492
Additional paid-in capital	43,718,498	43,411,143
Treasury stock, at cost	(23,602,061)	(23,431,685)
Accumulated deficit	(30,602,941)	(31,159,182)
Total stockholders' deficit	(10,338,012)	(11,031,232)
Total liabilities and stockholders' equity	61,710,774	61,220,770
Series A Junior Participating Preferred Stock [Member]
Stockholders' Deficit
Preferred stock	0	0
Tianhe Stem Cell Biotechnologies Inc [Member]
Other Assets
Investment	$ 308,000	$ 308,000

About CRYO-CELL International, Inc.

Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, and auto-immune diseases. The company also manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. The company was incorporated in 1989 and is headquartered in Oldsmar, Florida.

CEO	Mr. David I. Portnoy
WEBSITE	cryo-cell.com
INDUSTRY	Healthcare Plans
EMPLOYEES	80

CRYO-CELL International, Inc. Frequently Asked Questions

What is the ticker symbol for CRYO-CELL International, Inc.? What does CCEL stand for in stocks?

CCEL is the stock ticker symbol of CRYO-CELL International, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of CRYO-CELL International, Inc. (CCEL)?

As of Fri May 03 2024, market cap of CRYO-CELL International, Inc. is 73.1 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CCEL stock?

You can check CCEL's fair value in chart for subscribers.

What is the fair value of CCEL stock?

You can check CCEL's fair value in chart for subscribers. The fair value of CRYO-CELL International, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of CRYO-CELL International, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CCEL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is CRYO-CELL International, Inc. a good stock to buy?

The fair value guage provides a quick view whether CCEL is over valued or under valued. Whether CRYO-CELL International, Inc. is cheap or expensive depends on the assumptions which impact CRYO-CELL International, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CCEL.

What is CRYO-CELL International, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 03 2024, CCEL's PE ratio (Price to Earnings) is -7.51 and Price to Sales (PS) ratio is 2.33. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CCEL PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on CRYO-CELL International, Inc.'s stock?

In the past 10 years, CRYO-CELL International, Inc. has provided 0.097 (multiply by 100 for percentage) rate of return.